肿瘤坏死因子α抑制剂治疗（依那西普）对银屑病关节炎患者炎症生物标志物及软骨代谢血清浓度的影响。
The influence of tumour necrosis factor α inhibitors treatment - etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients.
作者信息
Waszczykowski Michał, Bednarski Igor, Lesiak Aleksandra, Waszczykowska Elżbieta, Narbutt Joanna, Fabiś Jarosław
机构信息
Department of Arthroscopy, Minimally Invasive Surgery and Sports Traumatology, Medical University of Lodz, Lodz, Poland.
Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of Lodz, Lodz, Poland.
出版信息
Postepy Dermatol Alergol. 2020 Dec;37(6):995-1000. doi: 10.5114/ada.2020.96705. Epub 2020 Jul 14.
INTRODUCTION
Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed.
AIM
To investigate whether biological treatment with anti-TNF-α (etanercept 50 mg once a week subcutaneously) affects the activity of selected mediators of inflammation and destruction of articular cartilage: interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinases 1 and 3 (MMP-1, MMP-3), cartilage oligomeric matrix protein (COMP), human cartilage glycoprotein (YKL-40) in serum of patients with PsA.
MATERIAL AND METHODS
The study included 25 patients with PsA. The concentration of IL-6, IL-18, MMP-1, MMP-3, COMP and YKL-40 in serum was determined before, and 6 and 12 weeks after the beginning of anti-TNF-α treatment. Clinical severity of the disease according to the Body Surface Area, Psoriasis Area and Severity Index and Dermatology Life Quality Index as well as tender and swollen joint count (TJC, SJC) were also evaluated.
RESULTS
The study disclosed a statistically significant reduction in the serum concentration of IL-6, MMP-1 and YKL-40 in PsA patients after 6 and 12 weeks from the beginning of anti-TNF-α treatment ( = 0.00018 for IL-6; = 0.01242 for MMP-1; = 0.03263 for YKL-40).
CONCLUSIONS
IL-6, MMP-1 and YKL-40 may be useful for monitoring the effectiveness of anti-TNF-α treatment.
引言
银屑病关节炎（PsA）患者的有效治疗可使其免受严重肌肉骨骼并发症的影响。为了对PsA患者的抗肿瘤坏死因子α（抗TNF-α）治疗进行适当监测，需要特定的生物标志物。
目的
研究抗TNF-α生物治疗（皮下注射依那西普50mg，每周一次）是否会影响PsA患者血清中选定的炎症介质和关节软骨破坏介质的活性：白细胞介素-6（IL-6）、白细胞介素-18（IL-18）、基质金属蛋白酶1和3（MMP-1、MMP-3）、软骨寡聚基质蛋白（COMP）、人软骨糖蛋白（YKL-40）。
材料与方法
该研究纳入了25例PsA患者。在抗TNF-α治疗开始前、治疗6周和12周后，测定血清中IL-6、IL-18、MMP-1、MMP-3、COMP和YKL-40的浓度。还评估了根据体表面积、银屑病面积和严重程度指数以及皮肤病生活质量指数以及压痛和肿胀关节计数（TJC、SJC）得出的疾病临床严重程度。
结果
研究显示，从抗TNF-α治疗开始6周和12周后，PsA患者血清中IL-6、MMP-1和YKL-40的浓度在统计学上显著降低（IL-6，P = 0.00018；MMP-1，P = 0.01242；YKL-40，P = 0.03263）。
结论
IL-6、MMP-1和YKL-40可能有助于监测抗TNF-α治疗的效果。
Zotero 插件